Cannabis Ruderalis

Methylenedioxycyclopropylmethyl­amphetamine
Names
Preferred IUPAC name
N-(Cyclopropylmethyl)-1-(2H-1,3-benzodioxol-5-yl)propan-2-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C14H19NO2/c1-10(15-8-11-2-3-11)6-12-4-5-13-14(7-12)17-9-16-13/h4-5,7,10-11,15H,2-3,6,8-9H2,1H3 ☒N
    Key: AEIQNPMGFQNZNV-UHFFFAOYSA-N ☒N
  • InChI=1/C14H19NO2/c1-10(15-8-11-2-3-11)6-12-4-5-13-14(7-12)17-9-16-13/h4-5,7,10-11,15H,2-3,6,8-9H2,1H3
    Key: AEIQNPMGFQNZNV-UHFFFAOYAQ
  • C3OC1C(C=CC(=C1)CC(C)NCC2CC2)O3
Properties
C14H19NO2
Molar mass 233.31 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

MDCPM, or 3,4-methylenedioxy-N-cyclopropylmethylamphetamine, is a lesser-known psychedelic drug. It is the N-cyclopropylmethyl derivative of MDMA. MDCPM was first synthesized by Alexander Shulgin; it is also one of the compounds delineated in a patent by Horrom in 1972.[1] In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 10 mg, and the duration unknown. MDCPM produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDCPM.

Legality[edit]

United Kingdom[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also[edit]

References[edit]

  1. ^ U.S. patent 3,689,504
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.

External links[edit]


Leave a Reply